Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Karima Benamara"'
Autor:
Alexandra Kopic, Tanja Ruthsatz, Hanspeter Rottensteiner, Frank M. Horling, Friedrich Scheiflinger, Werner Höllriegl, Alexander Bauer, Gerald Schrenk, Peter Leidenmühler, Martin J. Wolfsegger, Gerald Höbarth, Alfred Weber, Herbert Gritsch, Birgit M. Reipert, Helmut Glantschnig, Karima Benamara, Veronika Ehrlich, Michael Dockal, Maria Schuster, Peter Turecek
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 371:95-105
Extended half-life (EHL) factor therapies are needed to reduce the burden of prophylaxis and improve treatment adherence in patients with hemophilia. BAX 826 is a novel polysialylated full-length recombinant factor VIII [polysialyic acid (PSA) rFVIII
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da9442072f9ea3b0be9b7fc5c70e52a0
https://doi.org/10.1124/jpet.119.260067
https://doi.org/10.1124/jpet.119.260067
Autor:
Maria Schuster, Helmut Glantschnig, Werner Höllriegl, Alexandra Kopić, Alexander Bauer, Peter Leidenmühler, Karima Benamara
Publikováno v:
Laboratory Animals
Genetically engineered mouse models are used to investigate beneficial treatment in haemophilia by comparison with wild-type mice. It has been recognized that wild-type and haemophilic mice of different genetic backgrounds show different bleeding phe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bf82f73a650b6ab594bb39c69857f83
https://doi.org/10.1177/0023677218811059
https://doi.org/10.1177/0023677218811059
Autor:
Mantas Malisauskas, Josenato Ilas, Martin Feichtinger, Philipp Bärnthaler, Nina Pruckner, Julia Anzengruber, Karima Benamara, Birgit M. Reipert, Norbert Haider, Friedrich Scheiflinger
Publikováno v:
Pharmaceutical research. 36(5)
To explore how the natural heterogeneity of human coagulation factor VIII (FVIII) and the processing of its B-domain specifically modulate protein aggregation. Recombinant FVIII (rFVIII) molecular species containing 70% or 20% B-domain, and B-domain-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc5b30bfa825578fb016befe31c8d7ce
https://pubmed.ncbi.nlm.nih.gov/30937539
https://pubmed.ncbi.nlm.nih.gov/30937539
Autor:
Alexandra Löw-Baselli, Karima Benamara, Gerald Aichinger, Sandor Fritsch, Herwig Kollaritsch, Maikel V. W. van der Velden, Markus Zeitlinger, Otfried Kistner, Markus Müller, Hartmut J. Ehrlich, Eva Maria Pöllabauer, Timo Vesikari, P. Noel Barrett
Publikováno v:
Vaccine. 30:6127-6135
Background Influenza pandemic preparedness involves priming of the population with pre-pandemic vaccines. Such vaccines should be well tolerated and induce a long-lasting immunological memory that can effectively be boosted with a single dose of pand
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9592d1f048c9796213e132663f83f386
https://doi.org/10.1016/j.vaccine.2012.07.077
https://doi.org/10.1016/j.vaccine.2012.07.077
Autor:
Alexander Bauer, Peter Leidenmuehler, Karima Benamara, Gerald Hoebarth, Peter Turecek, Werner Hoellriegl, Martin J. Wolfsegger, Alexandra Kopić, Marietta Turecek
Publikováno v:
Blood. 128:2590-2590
To support the BAX 604 (FEIBA STAR) clinical study assessing different infusion rates and low volume reconstitution, the following nonclinical program was initiated: Two studies were performed in normal rats and FVIII-inhibited rabbits to evaluate th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a18c02c8fc004f7f89e5dc603b8088c
https://doi.org/10.1182/blood.v128.22.2590.2590
https://doi.org/10.1182/blood.v128.22.2590.2590
Autor:
Frank M. Horling, Friedrich Scheiflinger, Peter Turecek, Eva-Maria Muchitsch, Alexandra Schiviz, Karima Benamara, Hans Peter Schwarz, Barbara Dietrich, Hanspeter Rottensteiner, Werner Hoellriegl
Publikováno v:
International Journal of Hematology
Baxter has developed a new recombinant factor IX (rFIX) drug product (BAX326) for treating patients with hemophilia B, or congenital FIX deficiency. An extensive preclinical program evaluated the pharmacokinetics, efficacy, and safety of BAX326 in di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f023882f53f23a04e730355007db3ac4
https://pubmed.ncbi.nlm.nih.gov/24061775
https://pubmed.ncbi.nlm.nih.gov/24061775